EUCTR2015-001569-20-Outside-EU/EEA进行中（未招募）不适用
A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects with documented pre-established diagnosis of GHD with a GH peak response of <10 microgram/liter (mcg/L) with 2 GH stimulation tests, without priming with estradiol
- •Subjects with SGA defined as birth weight and/or length at least 2 standard deviations (SDs) below the mean for gestational age
- •Subjects with prepubertal status according to Tanner
- •Subjects with pre-established history of normal thyroid function or adequate substitution for at least 3 months
- •Subjects with weight for stature within the population specific normal range (>5th and <95th percentiles) for gender
- •Subjects with willingness and ability to comply with the protocol for the duration of the study
- •Subjects whose parents or guardians written informed consent given before any study-related procedure that was not part of the subjects normal medical care, with the understanding that the subject or parent/guardian might withdraw consent at any time without prejudice to future medical care. If the child was old enough to read and write, a separate assent form was given
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 205
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who acquired GHD due to central nervous system tumor, trauma, infection, infiltration (documented by imaging), and history of irradiation or cranial surgery
- •Subjects with previous treatment with GH, growth hormone releasing hormone (GHRH), anabolic steroids or any treatment affecting growth
- •Subjects who had previous treatment with corticosteroids, except in case of topical or inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal substitution were also allowed if the condition and the treatment regimen had been stable for at least 3 months
- •Subjects with severe associated pathology affecting growth such as malnutrition, malabsorption, or bone dysplasia
- •Subjects with chronic severe kidney disease
- •Subjects with chronic severe liver disease
- •Subjects with chronic infectious disease
- •Subjects with acute or severe illness during the previous 6 months
- •Subjects with significant concomitant illness that would interfere with participation or assessment in this study
- •Subjects who had active malignancy (except non-melanomatous skin malignancies that had undergone surgical excision and/or biopsy, diagnosis and treatment to resolution)
- •Subjects with history or active idiopathic intra-cranial hypertension (benign intracranial hypertension or pseudo-tumor cerebri)
- •Subjects with diabetes mellitus type I & II
- •Subjects with any autoimmune disease
- •Subjects who had previous screening failure in this study
- •Subjects who had used an investigational drug or participated in another clinical study within the last 3 months
研究者
相似试验
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with SaizeEUCTR2004-005054-31-SEMerck Serono International S.A.326
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saize- growth failure in children caused by decreased or absent secretion of endogenous growth hormone.- growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.MedDRA version: 7.1Level: PTClassification code 10056438EUCTR2004-005054-31-ATSerono International S.A.326
进行中（未招募）
1 期
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with SAIZEN.Estudio abierto en fase IV sobre marcadores predictivos en niños prepuberales con Déficit de Hormona de Crecimiento y síndrome de Turner tratados con Saizen R. - Predictive markers in GHD and TS children treated with SAIZEN.EUCTR2004-005054-31-ESSerono International S.A.318
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saize- growth failure in children caused by decreased or absent secretion of endogenous growth hormone.- growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.MedDRA version: 7.1Level: PTClassification code 10056438EUCTR2004-005054-31-DEMerck Serono International S.A.326
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.Growth failure in children caused by decreased or absent secretion of endogenous growth hormone - growth failure due to Tunner Syndrome.MedDRA version: 6.1Level: PTClassification code 10056438EUCTR2004-005054-31-ITINDUSTRIA FARMACEUTICA SERONO326